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PAS1
LEAVING AGAINST MEDICAL ADVICE (LAMA) IN ASTHMA
EXACERBATION: CHARACTERISTICS AND DETERMINANTS
OF LEAVERS
Tano BD
Johns Hopkins University School of Medicine, Baltimore, MD, USA
OBJECTIVE: Leaving against medical advice is a frustrating
event for physicians and medical staff and a costly behavior for
the patients. Studies have shown that in asthma exacerbation,
this decision by patients can lead to death. This study purports
to assess the determinants and characteristics of LAMA asth-
matic patients. METHODS: Healthcare Cost and Utilization
Project (HCUP) data are used. The study focuses on years
1997–2003 and only 2003 results are reported. Four Interna-
tional Classiﬁcation of Diseases, 9th Revision for asthma are
considered: Chronic obstructive asthma with acute exacerbation
(493.22), asthma without status asthmaticus (493.90), asthma
with status asthmaticus (493.91) and asthma with acute exacer-
bation (493.92). Results are reported based on these ICD-9 codes
respectively. RESULTS: Though the overall national LAMA rate
is less than one percent (0.84), it is found that LAMA is more
prevalent in asthmatic patients who are uninsured (2.9, 4.1, 4.1,
and 5.0%) compared with Medicare and Commercial insurance
LAMA rates that are both less than 1% in this database. LAMA
patients tend to have low income ($0–25,000) (1.7, 1.4, 1.5, and
2.7%) compared to not low income ($25,000+) (1.2, 1.0, 1.2,
and 1.6%), and are Medicaid recipients (2.9, 1.3, 1.3 and 2.7%).
The demographic characteristics of LAMA patients showed that
prime age asthmatics (ages 18–44) have the highest rates (3.3,
3.4, 4.5, and 4.8%), followed by middle age adults (ages 45–64)
(1.8, 1.5, 2.1, and 2.1%). The very young (ages < 1 and 1–17)
and the older adults (ages 65+) have minimal LAMA rates. Males
have slightly more LAMA rates than females (2.2, 1.1, 1.2,
2.5%) vs. (1.0, 1.1, 1.4, 1.8%) respectively. CONCLUSION:
Leaving AMA, a surrogate marker for non-adherence/non-
compliance in hospitalized patients coincides with poverty.
Therefore, educational measures used to remediate these 
behaviors can be used to help these patients.
PAS2
DRUG ADVERSE EVENTS MODIFY THE TREATMENT AND
COMPLIANCE OF ASTHMA PATIENTS
Laitinen T, Reissell E, Palmu PJ, Rehn M, Pirskanen A, Salonoja M,
Minkkinen S, Kunnas T
GeneOS Ltd, Helsinki, Finland
OBJECTIVE: A substantial proportion of adverse drug events
(ADE) are not reported because it is deemed to be either too well
known or the association between the drug and the adverse effect
is too doubtful. However, in clinical practice, mild to moderate
ADEs are common consequently increasing the costs of health
care and reducing the compliance of the patients. METHODS:
To analyze the patient or physician reported ADEs in asthma we
are in the process of screening the medical records and drug pur-
chase data for 1000 patients. The cohort consists of a random
sample of patients identiﬁed using the discharge registry of the
Helsinki University Hospital. RESULTS: Our initial results in the
patient cohort (mean age of 52, range from 24 to 65 years and
the proportion of females 62%) show that ADEs were reported
for 17% of the patients during the follow-up period of 5–10
years. Fifty-six percent of the reported ADEs were due to asthma
drugs and 64% of those led to changes in the patient’s medica-
tion. The medication was discontinued in 14% and the dose
reduced in 14% of the cases. In 36% the medication was dis-
continued and replaced with another product. Hospitalizations
due to ADE complications were also identiﬁed. In addition, 3%
of the patients were diagnosed with osteoporosis. All of them
had used per oral steroids, either only for asthma or for asthma
and a simultaneous autoimmune disease. Seven percent of
patients with LABA/SABA medication (and without any diag-
nosed heart condition) were treated due to tachyarrhythmias.
Twenty-four percent of the patients with simultaneous inhaled
corticosteroid therapy were diagnosed with oral Candida infec-
tion. CONCLUSIONS: Our data shows that even mild ADEs
have a signiﬁcant impact on the chosen therapy, the long term
medical outcome, and the costs of health care.
ASTHMA—Cost Studies
PAS3
ECONOMIC EVALUATION OF SYMBICORT®
(BUDESONIDE/FORMOTEROL) SINGLE-INHALER
MAINTENANCE AND RELIEVER THERAPY (SMART) IN
ASTHMA
Miller B1, Sears M2, Liovas A3
1Axia Research Inc, Hamilton, ON, Canada, 2McMaster University,
Hamilton, ON, Canada, 3AstraZeneca Canada Inc, Mississauga, ON,
Canada
OBJECTIVES: To compare the cost-effectiveness of budes-
onide/formoterol in a single inhaler used as maintenance and
reliever medication (Symbicort SMART) versus clinician directed
titration of maintenance ﬂuticasone/salmeterol (Advair) plus as-
needed salbutamol in controlling asthma in adults and adoles-
cents. METHODS: An economic evaluation was conducted
based on the results of a large (N = 2143), open-label, random-
ized, controlled effectiveness trial in which health resource 
utilization was prospectively collected. Primary outcome mea-
surements included time to ﬁrst exacerbation and number of
severe exacerbations. Costs included direct medical costs (physi-
cian/emergency room visits, hospitalizations, asthma drug costs)
and productivity (absenteeism). The time horizon was one-year
which corresponded to the duration of the trial. Prices were
obtained from 2005 Canadian sources. Both health care (HC)
and societal (Soc) perspectives were considered. Deterministic
univariate sensitivity analyses were conducted. RESULTS: In the
clinical trial, Symbicort was superior to Advair with respect to
the number of exacerbations, lung function and use of as-needed
rescue. The annualized rate of severe exacerbations was 0.24 in
the Symbicort arm and 0.31 in the Advair arm (p = 0.0025).
From the HC perspective, the mean cost per patient-year was
$1315 in the Symbicort arm versus $1541 in the Advair arm.
From the Soc perspective, it was $1538 for Symbicort and $1854
for Advair. Symbicort SMART was dominant (more effective,
less expensive) in the base case analysis from both the HC and
Soc perspectives. The results were robust under sensitivity
testing. CONCLUSIONS: The strategy of Symbicort SMART
which allows the combination of budesonide/formoterol to be
used as both maintenance and reliever medication is dominant
over a strategy of clinician directed titration of Advair (ﬂuticas-
one/salmeterol) therapy.
PAS4
ECONOMETRIC MODELING IN CHRONIC ASTHMA ALLOWS
COMPARISONS BETWEEN DIFFERENT THERAPY GROUPS
Palmu PJ, Reissell E, Laitinen T, Rehn M, Pirskanen A, Salonoja M,
Minkkinen S, Kunnas T
GeneOS Ltd, Helsinki, Finland
OBJECTIVES: We evaluated the severity of chronic asthma and
the resulting economic burden by assessing the use and costs of
